Gustavo Scaffa - ImmuCell Director Quality
| ICCC Stock | USD 3.70 0.04 1.07% |
Insider
Gustavo Scaffa is Director Quality of ImmuCell
| Address | 56 Evergreen Drive, Portland, ME, United States, 04103 |
| Phone | 207 878 2770 |
| Web | https://immucell.com |
ImmuCell Management Efficiency
The company has return on total asset (ROA) of (0.0487) % which means that it has lost $0.0487 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.161) %, meaning that it created substantial loss on money invested by shareholders. ImmuCell's management efficiency ratios could be used to measure how well ImmuCell manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.13. The current year's Return On Capital Employed is expected to grow to -0.14. At present, ImmuCell's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 36.5 B, whereas Non Currrent Assets Other are forecasted to decline to about 54.8 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| RAC Sakai | Tempest Therapeutics | N/A | |
| Gordon Sanghera | Oxford Nanopore Technologies | N/A | |
| Andrew Slee | Protagenic Therapeutics | 74 | |
| Hing Wong | HCW Biologics | 70 | |
| Dr MBA | MediciNova | 59 | |
| Lucie Larguier | Transgene SA | N/A | |
| John CPA | MediciNova | N/A | |
| Anne McKay | Fennec Pharmaceuticals | 70 | |
| Robert MD | Protagenic Therapeutics | 73 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| MS MBA | XOMA Corporation | 67 | |
| Philippe Slos | Transgene SA | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Sarah Lapworth | Oxford Nanopore Technologies | N/A | |
| Rhodri Davies | Oxford Nanopore Technologies | N/A | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Thomas Burns | XOMA Corporation | 49 | |
| DVM Dvm | Lineage Cell Therapeutics | 53 | |
| Susan MS | Eliem Therapeutics | N/A | |
| John Schoellerman | Oxford Nanopore Technologies | N/A | |
Management Performance
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0487 |
ImmuCell Leadership Team
Elected by the shareholders, the ImmuCell's board of directors comprises two types of representatives: ImmuCell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmuCell. The board's role is to monitor ImmuCell's management team and ensure that shareholders' interests are well served. ImmuCell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmuCell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth Williams, Vice President - Manufacturing Operations | ||
| Bobbi Brockmann, VP of Sales and Marketing | ||
| Elizabeth Toothaker, Director Administration | ||
| Michael Brigham, CEO and President CFO, Treasurer, Secretary and Director | ||
| John Zinckgraf, Director Development | ||
| Gustavo Scaffa, Director Quality |
ImmuCell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ImmuCell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0487 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | (0.25) % | ||||
| Current Valuation | 45.05 M | ||||
| Shares Outstanding | 8.91 M | ||||
| Shares Owned By Insiders | 39.52 % | ||||
| Shares Owned By Institutions | 14.51 % | ||||
| Number Of Shares Shorted | 4.01 K | ||||
| Price To Earning | 195.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.